CTOs on the Move

AiVita Biomedical

www.aivitabiomedical.com

 
AIVITA Biomedical is a privately held company engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

AiVita Biomedical raised $15M on 06/11/2018
AiVita Biomedical raised $25M on 12/29/2020

Similar Companies

HealthLoop

HealthLoop automates patient engagement to help health providers reduce cost, improve outcomes and deliver a 5-star patient experience. Reassuring guidance each step of the way connects care teams with patients who need it most. HealthLoop enables value-based care for hospitals to monitor at-risk populations, provide outreach when most needed and track patients through an episode of care. Patients rate their doctors with a 5-star experience and providers realize better efficiencies with an automated patient check-in approach. Located in Mountain View, HealthLoop facilitates over 25,000 automated check-ins each month.

Verax Biomedical Incorporated

Verax Biomedical Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Omnicare Distribution Center

Omnicare Distribution Center is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MBX Biosciences

MBX Biosciences is a preclinical-stage biotechnology company using validated molecular targets to create medicines for rare endocrine diseases where current therapies are inadequate.

Code Biotherapeutics

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to treat the untreatable and cure the incurable. Code Bio is developing highly targeted genetic medicines with its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with the delivery of genetic medicines. 3DNA offers unparalleled tissue and cell targeting specificity, improved bioavailability, capability to deliver large genetic payloads, potential ability to re-dose, and a scalable, modular, reproducible manufacturing process. Our 3DNA delivery platform is poised to transform the field of genetic medicines, enabling targeted delivery of gene therapy, RNAi and other genetic modalities. Currently we are advancing an internal pipeline of genetic medicines focused on select diseases without a cure (Duchenne`s Muscular Dystrophy and Type 1 Diabetes), as well as establishing partnerships to take forward programs in both rare and prevalent diseases.